Daratumumab for maintenance in myeloma
In this issue of Blood, Badros and colleagues present the results from AURIGA, the first phase 3 randomized trial comparing daratumumab lenalidomide (DR) t
Related Articles
Frontline management of multiple myeloma patients: optimizing treatment for patients in the Gulf region | Published in Clinical Hematology International
By Mahmoud Marashi, Khalil Al Farsi & 8 more. Treatment options for newly diagnosed multiple myeloma (NDMM) have expanded dramatically over the last two decades,…
Tackling inequality through data: the professor of primary care
Professor of primary care and public health Azeem Majeed talks to Carla Delgado about his passion for tackling health inequalities through data As a medical…
Welcome! You are invited to join a webinar: IACH Webinar- Therapy of Haemohilia: Where do we stand?. After registering, you will receive a confirmation email about joining the webinar.
Speaker: Gili Kenet Prof. Gili Kenet is a Pediatric Hematologist, Professor and chair of the Haematology department at the Sackler Medical School, Tel Aviv University,…
22 states sue to block Trump administration cuts to NIH research payments
Attorneys general sued the Trump administration to block a NIH decision that would slash grant payments for research overhead
Menin inhibitors in the treatment of acute myeloid leukemia
In this Blood Spotlight, Huls et al highlight why small molecule inhibitors of menin are creating excitement in the acute myeloid leukemia (AML) field with
Diagnosis of myelodysplastic syndromes: the classic and the novel
The myelodysplastic syndromes (MDS) are a heterogenous group of clonal bone marrow (BM) stem cell myeloid neoplasms, characterized by BM dysplasia, macrocytic anemia or cytopenia…
Brown University doctors team up to create a new device for modern cancer surgeries – The Boston Globe
“What we’ve done is create an instrument where your hands don’t need to be inside the body,” said Dr. David Wazer. “It can be done…
Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer (SCLC): the phase I/II LUPER study
Small-cell lung cancer (SCLC) has limited second-line treatment options after chemotherapy. We assessed the efficacy and safety of lurbinectedin combined with pembrolizumab in relapsed SCLC…
Program Guide – ASCO Meeting Program Guide
Nicolas Sayegh , Yeonjung Jo , Umang Swami , Chadi Hage Chehade , Zeynep Irem Ozay , Georges Gebrael , Benjamin Maughan , Melissa Plets…
Program Guide – ASCO Meeting Program Guide
Giulio Francolini Radiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence Giulio Francolini , Vanessa Di Cataldo , Pietro Garlatti , Saverio Caini ,…